Table 2 Trends in Management of Patients with De Novo Metastatic Breast Cancer in an Asian Setting.
Characteristics | Overall (856 patients) N, % | Period of diagnosis | P valuea | ||
|---|---|---|---|---|---|
1996–2000 (130 patients) n, % | 2001–2005 (287 patients) n, % | 2006–2010 (439 patients) n, % | |||
Surgery of primary tumor | 0.001 | ||||
No | 534 (62.4) | 86 (66.2) | 189 (65.9) | 259 (59.0) | |
Mastectomy | 301 (35.2) | 36 (27.7) | 90 (31.4) | 175 (39.9) | |
Breast conserving surgery | 21 (2.5) | 8 (6.2) | 8 (2.8) | 5(1.1) | |
Surgical marginsb | 0.006 | ||||
Free | 187 (73.0) | 13 (52.0) | 43 (63.2) | 131 (80.4) | |
Positive | 69 (27.0) | 12 (48.0) | 25 (36.8) | 32 (19.6) | |
Unknown | 66 | 19 | 30 | 17 | |
Radiotherapy to breast/chest wall/other sites | 0.126 | ||||
Yes | 220 (33.7) | 24 (23.3) | 65 (37.8) | 131 (34.7) | |
No | 432 (66.2) | 79 (76.7) | 107 (62.2) | 246 (65.1) | |
Unknown | 204 | 27 | 115 | 62 | |
Chemotherapy, n (%) | 0.008 | ||||
Yes | 460(59.2) | 71 (54.6) | 109 (52.4) | 280 (63.8) | |
No | 314(40.8) | 59 (45.4) | 99 (47.6) | 156 (35.8) | |
Unknown | 82 | 0 | 79 | 3 | |
Endocrine therapyc | 0.263 | ||||
Yes | 212 (59.1) | 13 (44.8) | 65 (59.6) | 134 (60.6) | |
No | 147 (40.9) | 16 (55.2) | 44 (40.4) | 87 (39.4) | |
Unknown | 74 | 2 | 46 | 26 | |
